These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21139590)
1. Synthetic DNA firms embrace hazardous agents guidance but remain wary of automated 'best-match'. Eisenstein M Nat Biotechnol; 2010 Dec; 28(12):1225-6. PubMed ID: 21139590 [No Abstract] [Full Text] [Related]
2. Strengths and limitations of the federal guidance on synthetic DNA. Adam L; Kozar M; Letort G; Mirat O; Srivastava A; Stewart T; Wilson ML; Peccoud J Nat Biotechnol; 2011 Mar; 29(3):208-10. PubMed ID: 21390018 [No Abstract] [Full Text] [Related]
3. HHS guidance on synthetic DNA is the right step. Gronvall GK Biosecur Bioterror; 2010 Dec; 8(4):373-6. PubMed ID: 21142764 [TBL] [Abstract][Full Text] [Related]
4. [On studies with medicines after commercialization, obligations or prohibitions?]. Sádaba B An Sist Sanit Navar; 2003; 26(2):187-93. PubMed ID: 12951613 [No Abstract] [Full Text] [Related]
5. Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry. Olson MJ; Binks SP; Newton DL; Clark GC Occup Med; 1997; 12(1):49-65. PubMed ID: 9153052 [TBL] [Abstract][Full Text] [Related]
10. California shows the way for biosecurity in commercial gene synthesis. West R; Gronvall GK Nat Biotechnol; 2020 Sep; 38(9):1021. PubMed ID: 32811990 [No Abstract] [Full Text] [Related]
12. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Hoffman FA; Heimbach JT; Sanders ME; Hibberd PL Clin Infect Dis; 2008 Feb; 46 Suppl 2():S53-7. PubMed ID: 18181723 [No Abstract] [Full Text] [Related]
13. Quality assurance mechanisms for the unregulated research environment. Riedl DH; Dunn MK Trends Biotechnol; 2013 Oct; 31(10):552-4. PubMed ID: 24054820 [TBL] [Abstract][Full Text] [Related]
14. Synthetic biology and the freedom of scientific research: a fundamental freedom in front of a new emerging technology. Colussi I Rev Derecho Genoma Hum; 2014; Spec No():277-87. PubMed ID: 24915711 [No Abstract] [Full Text] [Related]
15. Biotech firms look for virtual success. Schmidt C Cancer Discov; 2012 Jan; 2(1):OF5. PubMed ID: 22585175 [No Abstract] [Full Text] [Related]
16. Comment on: developing good scientific publishing practices: one pharmaceutical company's perspective. Norris RA Curr Med Res Opin; 2010 Jul; 26(7):1675-6. PubMed ID: 20450261 [No Abstract] [Full Text] [Related]
17. Developing a clinical trial governance framework for pharmaceutical industry-funded clinical trials. Nair SC; AlGhafli S; AlJaberi A Account Res; 2018; 25(7-8):373-386. PubMed ID: 30249125 [TBL] [Abstract][Full Text] [Related]
18. Health hazard labeling for hazard communication in the pharmaceutical industry. Sussman RG; Kimmel TA; Neske FW Occup Med; 1997; 12(1):107-17. PubMed ID: 9153056 [TBL] [Abstract][Full Text] [Related]
20. The EPA's new chemicals program under TSCA. Culleen LE Qual Assur; 1993; 2(1-2):121-6. PubMed ID: 8156198 [No Abstract] [Full Text] [Related] [Next] [New Search]